Aclaris therapeutics announces exclusive, global license agreement with biosion, inc., adding potential best-in-class biologics assets to pipeline

- enhances aclaris' pipeline with complementary biologics portfolio - - expands leadership team with addition of seasoned biotech executives - - management to host conference call today at 8:30 am et - wayne, pa., nov. 18, 2024 (globe newswire) --  aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with biosion, inc. (biosion) for worldwide rights (excluding greater china) to bsi-045b, a potential best-in-class, clinical-stage, novel anti-tslp monoclonal antibody, and bsi-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both tslp and il4r.
ACRS Ratings Summary
ACRS Quant Ranking